Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension

Cardiovascular outcome trials demonstrated that GLP-1 (glucagon-like peptide-1) analogs including liraglutide reduce the risk of cardiovascular events in type 2 diabetes mellitus. Whether GLP-1 analogs reduce the risk for atherosclerosis independent of glycemic control is challenging to elucidate as...

Descripción completa

Detalles Bibliográficos
Autores principales: Helmstädter, Johanna, Frenis, Katie, Filippou, Konstantina, Grill, Alexandra, Dib, Mobin, Kalinovic, Sanela, Pawelke, Franziska, Kus, Kamil, Kröller-Schön, Swenja, Oelze, Matthias, Chlopicki, Stefan, Schuppan, Detlef, Wenzel, Philip, Ruf, Wolfram, Drucker, Daniel J., Münzel, Thomas, Daiber, Andreas, Steven, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Basic Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946108/
https://www.ncbi.nlm.nih.gov/pubmed/31747801
http://dx.doi.org/10.1161/atv.0000615456.97862.30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946108/
https://www.ncbi.nlm.nih.gov/pubmed/31747801
http://dx.doi.org/10.1161/atv.0000615456.97862.30

Ejemplares similares